Ureas

AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 16, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical trials, Cancer treatments, Clinical medicine, Drugs, Ureas, Monoclonal antibodies, Antineoplastic drugs, Breakthrough therapy, Tivozanib, Nivolumab, Hepatocellular carcinoma, FOTIVDA® (tivozanib), Advanced Renal Cell Carcinoma, AVEO Pharmaceuticals, Inc.

AVEO Oncology (Nasdaq: AVEO) today reported financial results for the full year ended December 31, 2020 and provided a business update.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today reported financial results for the full year ended December 31, 2020 and provided a business update.
  • Results from Phase 1b Portion of DEDUCTIVE Study in Hepatocellular Carcinoma (HCC) Presented at 2021 ASCO GI Cancer Symposium.
  • Results from Phase 1b/2 TiNivo Study of Tivozanib in Combination with OPDIVO (nivolumab) in RCC Published in Annals of Oncology.
  • While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anti-Cancer Agent Lenvima (Lenvatinib) With Prospective Indication for Uterine Body Cancer

Retrieved on: 
Friday, March 12, 2021
Drugs, Orphan drugs, Cancer treatments, Health sciences, Chloroarenes, Ureas, Eisai, Lenvatinib, Protein kinase inhibitor, Progression-free survival, Pembrolizumab, Clinical endpoint

TOKYO, Mar 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of Health, Labour and Welfare (MHLW).

Key Points: 
  • TOKYO, Mar 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of Health, Labour and Welfare (MHLW).
  • In this study, LENVIMA plus KEYTRUDA met its dual primary endpoints, overall survival (OS) and progression-free survival (PFS), as well as its secondary efficacy endpoint of objective response rate (ORR).
  • Currently, Eisai is preparing to submit an application for additional indications based on these results in various countries around the world including Japan.
  • Eisai positions oncology as a key therapeutic area and is aiming to discover innovative new medicines with the potential to cure cancer.

Pimavanserin: A Selective Serotonin Inverse Agonist and Antagonist Preferentially Targeting 5-HT2A Receptors - Global Emerging Insights and Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 10, 2021
Health, Pharmaceutical, Branches of biology, Chemical compounds, Organic compounds, Piperidines, Atypical antipsychotics, 5-HT2A antagonists, Pimavanserin, Ureas, 5-HT2A receptor, Serotonin, Psychosis, Agonist

The "Pimavanserin - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pimavanserin - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors.
  • These receptors are thought to play an important role in psychosis, schizophrenia, depression and other neuropsychiatric disorders.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH

Retrieved on: 
Tuesday, March 9, 2021
Chemical compounds, Pyrimidines, Organic compounds, Organofluorides, Chemistry, Pyrrolidines, Orphan drugs, Ureas, Brilacidin

These data from the China cohort are consistent with those of the US cohort, previously reported at the AASLD Liver Meeting in November 2020.

Key Points: 
  • These data from the China cohort are consistent with those of the US cohort, previously reported at the AASLD Liver Meeting in November 2020.
  • "Based on the positive Phase 2 data, we have selected doses for the Phase 2b/3 NASH trial in China."
  • The China cohort of this Phase 2 trial evaluated the safety and efficacy of an oral, once-daily dosing of 50 mg of ASC40 or matching placebo for 12 weeks in 30 patients with NASH.
  • In 63% of patients on ASC40 ALT decreased by17 U/L or greater, which has been shown to correlate with liver biopsy response in NASH patients.

Sumitovant Biopharma’s Portfolio of Innovative Companies Achieve Significant Clinical and Corporate Milestones in its Third Quarter of Operation

Retrieved on: 
Tuesday, March 2, 2021
Chemical compounds, Organic compounds, Chemistry, Ethers, Pyrimidines, Relugolix, Triketones, Ureas, Roivant Sciences, Prostate cancer

today announced that its five subsidiary healthcare companies ( Myovant , Urovant , Enzyvant , Altavant and Spirovant ) achieved multiple clinical and corporate milestones in the companys third quarter ending on December 31, 2020.

Key Points: 
  • today announced that its five subsidiary healthcare companies ( Myovant , Urovant , Enzyvant , Altavant and Spirovant ) achieved multiple clinical and corporate milestones in the companys third quarter ending on December 31, 2020.
  • We are pleased to see so much progress in Sumitovants third quarter of operation.
  • On December 18, 2020, the FDA approved Myovants ORGOVYXTM (relugolix) for the treatment of adult patients with advanced prostate cancer.
  • Sumitovant is the majority shareholder of Myovant Sciences and Urovant Sciences, and wholly owns Enzyvant Therapeutics, Spirovant Sciences, and Altavant Sciences.

Jubilant Therapeutics Announces Research Collaboration with Boston Children's Hospital, Harvard Medical School, to Evaluate PAD4 Inhibitors in Autoimmune/Inflammation Disease Models

Retrieved on: 
Thursday, February 25, 2021
Amino acids, Citrulline, Urea cycle, Ureas, Chemistry, Physical sciences

PAD4 is an enzyme that converts arginine to citrulline in histones and is highly expressed in neutrophils.

Key Points: 
  • PAD4 is an enzyme that converts arginine to citrulline in histones and is highly expressed in neutrophils.
  • Specific PAD4 inhibitors, that are well tolerated by animals, would be great for pre-clinical and, later, human studies.
  • Jubilant Therapeutics Inc. is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases.
  • Jubilant Therapeutics is headquartered in the U.S. and guided by globally renowned key opinion leaders and scientific advisory board members.

Jubilant Therapeutics Announces Research Collaboration with Boston Children's Hospital, Harvard Medical School, to Evaluate PAD4 Inhibitors in Autoimmune/Inflammation Disease Models

Retrieved on: 
Thursday, February 25, 2021
Amino acids, Citrulline, Urea cycle, Ureas, Chemistry, Physical sciences

PAD4 is an enzyme that converts arginine to citrulline in histones and is highly expressed in neutrophils.

Key Points: 
  • PAD4 is an enzyme that converts arginine to citrulline in histones and is highly expressed in neutrophils.
  • Specific PAD4 inhibitors, that are well tolerated by animals, would be great for pre-clinical and, later, human studies.
  • Jubilant Therapeutics Inc. is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases.
  • Jubilant Therapeutics is headquartered in the U.S. and guided by globally renowned key opinion leaders and scientific advisory board members.

Jubilant Therapeutics Announces Research Collaboration with Boston Children's Hospital, Harvard Medical School, to Evaluate PAD4 Inhibitors in Autoimmune/Inflammation Disease Models

Retrieved on: 
Thursday, February 25, 2021
Amino acids, Citrulline, Urea cycle, Ureas, Chemistry, Physical sciences

PAD4 is an enzyme that converts arginine to citrulline in histones and is highly expressed in neutrophils.

Key Points: 
  • PAD4 is an enzyme that converts arginine to citrulline in histones and is highly expressed in neutrophils.
  • Specific PAD4 inhibitors, that are well tolerated by animals, would be great for pre-clinical and, later, human studies.
  • Jubilant Therapeutics Inc. is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases.
  • Jubilant Therapeutics is headquartered in the U.S. and guided by globally renowned key opinion leaders and scientific advisory board members.

Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant Sciences Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

Retrieved on: 
Thursday, February 18, 2021
Chemical compounds, Drugs, Organic compounds, GnRH antagonists, Ethers, Triketones, Pyrimidines, Relugolix, Ureas, Menstruation, Uterine fibroid, Medroxyprogesterone acetate

Peer-reviewed publication of these two important studies in the New England Journal of Medicine is a significant step forward for women who suffer from uterine fibroids, said Myrtle Potter, chief executive officer of Sumitovant Biopharma.

Key Points: 
  • Peer-reviewed publication of these two important studies in the New England Journal of Medicine is a significant step forward for women who suffer from uterine fibroids, said Myrtle Potter, chief executive officer of Sumitovant Biopharma.
  • On average, women receiving relugolix combination therapy experienced an 84.3% reduction in menstrual blood loss from baseline in each study (both p
  • Data showed changes in bone mineral density were comparable between the relugolix combination and placebo groups at the end of treatment in LIBERTY 1 and LIBERTY 2.
  • Sumitovant is the majority shareholder of Myovant Sciences and Urovant Sciences, and wholly owns Enzyvant Therapeutics, Spirovant Sciences, and Altavant Sciences.

BIAL Takes the Lead in Europe for the Commercialisation of Epilepsy Treatment, Zebinix® (eslicarbazepine acetate), Expanding Neurology Footprint

Retrieved on: 
Thursday, February 18, 2021
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Bial, Epilepsy, Anticonvulsants, Ureas, Health, Eslicarbazepine acetate, Epilepsy in animals, Chemistry, Zebinix® (eslicarbazepine acetate), Epilepsy, BIAL

BIAL takes the lead for the marketing and distribution of Zebinix (eslicarbazepine acetate) in Europe.

Key Points: 
  • BIAL takes the lead for the marketing and distribution of Zebinix (eslicarbazepine acetate) in Europe.
  • Following the end of this partnership, BIAL will take the lead for the ongoing marketing, promotion and distribution in Europe.
  • BIAL has over 10 years of experience of delivering life-improving medicines for neurological conditions such as epilepsy and Parkinsons disease.
  • For more information on BIAL: www.bial.com
    1- Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe.